The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials

Pharmacological Research

Volumn 103, Issue , 2016, Pages 49-55

  Mihos, Christos G ^a   Krishna, Rama K ^b   Kherada, Nisharahmed ^b   Larrauri Reyes, Maiteder ^b   Tolentino, Alfonso ^b   Santana, Orlando ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Mount Sinai Heart Institute ^*  (United States)

Author keywords

Cardiovascular effects; Non anginal; Randomized trials; Ranolazine

Indexed keywords

AMIODARONE; DRONEDARONE; PLACEBO; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVERSION; CHRONIC ATRIAL FIBRILLATION; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; MICROVASCULAR DYSFUNCTION; MONOTHERAPY; NEW-ONSET ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PAROXYSMAL ATRIAL FIBRILLATION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE ATRIAL FIBRILLATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SUDDEN CARDIAC DEATH; CARDIOVASCULAR DISEASES;

CARDIOVASCULAR DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANOLAZINE; SODIUM CHANNEL BLOCKERS;

EID: 84947976046     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.10.018     Document Type: Review

References (62)

1. J.C. Shryock, Y. Song, S. Rajamani, and et al. The arrhythmogenic consequences of increasing late INa in the cardiomyocyte Cardiovasc. Res. 99 2013 600 611
2. L. Belardinelli, J.C. Shryock, and H. Fraser Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine Heart 92 Suppl. 4 2006 iv6 iv14
3. C. Antzelevitch, L. Belardinelli, A.C. Zygmunt, and et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties Circulation 110 2004 904 910
4. A.O. Grant Cardiac ion channels Circulation 2 2009 185 194
5. + current in human ventricular cardiomyocytes Cardiovasc. Res. 69 2006 116 127
6. C. Antzelevitch, V. Nesterenko, J.C. Shryock, and et al. The role of late I Na in development of cardiac arrhythmias Handb Exp. Pharmacol. 221 2014 137 168
7. D. Noble, and P.J. Noble Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload Heart 92 Suppl. 4 2006 iv1 iv5
8. + current-origin and pathophysiological relevance Cardiovasc. Drugs Ther. 27 2013 61 68
9. A. Burashnikov, and C. Antzelevitch Role of late sodium channel current block in the management of atrial fibrillation Cardiovasc. Drugs Ther. 27 2013 79 89
10. D.K. Murdock, M. Kersten, J. Kaliebe, and et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible pill in the pocket approach to atrial fibrillation Indian Pacing Electrophysiol. J. 9 2009 260 267
11. K.C. Koskinas, N. Fragakis, D. Katritsis, and et al. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation Europace 16 2014 973 979
12. N. Fragakis, K.C. Koskinas, D.G. Katritsis, and et al. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation Am. J. Cardiol. 110 2012 673 677
13. B.M. Scirica, D.A. Morrow, H. Hod, and et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-Elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652
14. P.R. Kowey, J.A. Reiffel, A.J. Camm, and et al. The effect of the combination of ranolazine and low dose dronedarone on atrial fibrillation burden in patients with paroxysmal atrial fibrillation (HARMONY trial) Heart Rhythm Society 2014 Scientific Sessions May 10, San Francisco, CA 2014 Abstract LB03-05.
15. Y.K. Iwasaki, K. Nishida, T. Kato, and et al. Atrial fibrillation pathophysiology: implications for management Circulation 124 2011 2264 2274
16. A. Burashnikov, J.M. Di Diego, A.C. Zygmunt, and et al. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation Ann. N. Y. Acad. Sci. 1123 2008 105 112
17. D.K. Murdock, N. Overton, M. Kersten, and et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation Indian Pacing Electrophysiol. J. 8 2008 175 181
18. F. De, G.M. errari, L.S. Maier, L. Mont, and et al. Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study Heart Rhythm 12 2015 872 878
19. D.K. Murdock, J. Kaliebe, and G. Larrain The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series Pacing Clin. Electrophysiol. 35 2012 302 307
20. L.D. Hillis, P.K. Smith, J.L. Anderson, and et al. ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines Circulation 124 2011 652 735
21. N. Fragakis, K.C. Koskinas, and V. Vassilikos Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications Pacing Clin. Electrophysiol. 37 2014 1412 1420
22. G.I. Tagarakis, I. Aidonidis, S.S. Daskalopoulou, and et al. Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery Curr. Vasc. Pharmacol. 11 2013 988 991
23. V. Simopoulos, G.I. Tagarakis, S.S. Daskalopoulou, and et al. Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery Angiology 65 2014 294 297
24. S. Bekheit Ranolazine for the prevention of atrial fibrillation after electrical cardioversion Clinicaltrials 2012 gov Identifier: NCT01590979
25. R.H. Miles, R. Passman, and D.K. Murdock Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting Am. J. Cardiol. 108 2011 673 676
26. D.A. Hammond, C. Smotherman, C.A. Jankowski, and et al. Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries Clin. Res. Cardiol. 104 2015 410 417
27. W.R. Herzog, R.A. Vogel, M.L. Schlossberg, and et al. Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size Int. J. Cardiol. 59 1997 21 27
28. 2+]m overload in rat hearts Am. J. Physiol. 271 1996 H2145 H2153
29. F. Pelliccia, V. Pasceri, G. Marazzi, and et al. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention Am. Heart J. 163 2012 1019 1023
30. G. Weisz, R. Farzaneh-Far, O. Ben-Yehuda, and et al. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the ranolazine for incomplete vessel revascularization post-percutaneous coronary intervention (RIVER-PCI) trial Am. Heart J. 166 2013 953 959
31. F. Pelliccia Ranolazine loading to prevent PCI-induced myocardial injury (TWILIGHT) Clinicaltrials 2013 gov Identifier: NCT01491061
32. P. Yue Effect of ranolazine on myocardial perfusion assessed by serial quantitative exercise SPECT imaging Clinicaltrials 2014 gov Identifier: NCT01221272
33. S. Blankenberg Reduction of ischemic myocardium with ranolazine-teatment in patients with acute myocardial ischemia (RIMINI) Clinicaltrials 2015 gov Identifier: NC T017 9748 4
34. A. Beyder, P.R. Strege, S. Reyes, and et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v) 1.5: a novel mechanism of drug action Circulation 125 2012 2698 2706
35. E. Yeung, M.J. Krantz, J.L. Schuller, and et al. Ranolazine for the suppression of ventricular arrhythmia: a case series Ann. Noninvasive Electrocardiol. 19 2014 345 350
36. T.J. Bunch, S. Mahapatra, D. Murdock, and et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks Pacing Clin. Electrophysiol. 34 2011 1600 1606
37. W. Zareba Ranolazine implantable cardioverter-defibrillator trial (RAID) Clinicaltrials 2015 gov Identifier: NCT01215253
38. M.S. Cahill Study to reduce symptoms of premature beats with ranolazine Clinicaltrials 2013 gov Identifier: NCT01648205
39. W. Zareba Efficacy study of sodium channel blocker in Long QT syndrome type 3 Clinicaltrials 2015 gov Identifier: NCT01648205
40. D. Doshi, and S.O. Marx Ion channels transporters, and pumps as targets for heart failure therapy J. Cardiovasc. Pharmacol. 54 2009 273 278
41. V.M. Figueredo, G.S. Pressman, A. Romero-Corral, and et al. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina J. Cardiovasc. Pharmacol. Ther. 16 2011 168 172
42. L.S. Maier, B. Layug, E. Karwatowska-Prokopczuk, and et al. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study JACC Heart Fail 1 2013 115 122
43. N.W. Shammas, G.A. Shammas, K. Keyes, and et al. Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study Ther. Clin. Risk Manag. 11 2015 469 474
44. D.B. Barnard The effects of ranolazine on exercise capacity in patients with heart failure with preserved ejection fraction Clinicaltrials. 2013 gov Identifier: NCT0150517 9
45. N. Bairey-Merz Treatment with ranolazine in microvascular coronary dysfunction: impact on angina myocardial ischemia (RWISE) Clinicaltrials 2015 gov Identifier: NCT01342029
46. H. Samady Microvascular assessment of ranolazine in non-obstructive atherosclerosis (MARINA) Clinicaltrials 2015 gov Identifier: NCT02147067
47. N. Bairey-Merz Microvascular coronary disease in women: impact of ranolazine Clinicaltrials 2015 gov Identifier:NCT00570089
48. G. Minotti, P. Menna, E. Salvatorelli, and et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
49. G. Minotti Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs J. Pharmacol. Exp. Ther. 346 2013 343 349
50. F. Corradi, L. Paolini, C. De, and R. aterina Ranolazine in the prevention of anthracycline cardiotoxicity Pharmacol. Res. 79 2014 88 102
51. C.G. Tocchetti, A. Carpi, C. Coppola, and et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction Eur. J. Heart Fail 16 2014 358 366
52. G. Minotti The ranolazine to treat early cardiotoxicity induced by antitumor drugs (INTERACT) study Eur. Clin. Trials 2013 Database Identifier: 2009-016930-29
53. R. Baljepally Ranolazine effects on ischemic mitral regurgitation severity in patients with cardiac resynchronization therapy (REIN-MR) Clinicaltrials 2013 gov Identifier: NCT01979965
54. L. Fanny Supervised treadmill exercise and ranolazine for intermittent claudication of lower extremities (STERILE) Clinicaltrials 2013 gov Identifier: NCT00914316
55. Y.A. Han Randomized double-blind, placebo controlled, multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative study of cellular metabolism in subjects with pulmonary hypertension with and without right ventricular dysfunction Clinicaltrials 2015 gov Identifier: NCT01839110
56. M.A. Gomberg-Maitland Phase I. study of ranolazine acute administration and short term administration in pulmonary arterial hypertension Clinicaltrials 2015 gov Identifier: NCT01757808
57. A.J. Moss, W. Zareba, K.Q. Schwarz, and et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome J. Cardiovasc. Electrophysiol. 19 2008 1289 1293
58. B. den, M.P. erg, H. den, F. euvel, T. van, J.P. intelen, and et al. Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker Int. J. Cardiol. 171 2014 90 92
59. J.D. Moreno, P.C. Yang, J.R. Bankston, and et al. Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening Circ. Res. 113 2013 e50 e61
60. J.T. Liles, K. Hoyer, J. Oliver, and et al. Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension J. Pharmacol. Exp. Ther. 353 2015 480 489
61. R.L. Verrier, A.F. Silva, R. Bonatti, and et al. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation J. Cardiovasc. Electrophysiol. 26 2015 329 335
62. S.D. Fihn, J.C. Blankenship, K.P. Alexander, and et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation 130 2014 1749 1767 2014